4
Changes in Ownership
Vaxcyte, Inc. Filed Acc 0001649094-24-000038
PRESIDENT AND CFO sold 8,000 shares at an average $81.17 ($649,325)
- PRESIDENT AND CFO acquired 8,000 shares (option exercise)
- Traded under a Rule 10b5-1 plan
From the SEC's structured data for this filing
Trades in this filing
| Insider | Date | Transaction | Shares | Price | Value | Owned after | D/I |
|---|---|---|---|---|---|---|---|
| GUGGENHIME ANDREW PRESIDENT AND CFO | 2024-07-18 | Option exercise 10b5-1 | +8,000 | $5.35 | $42,800 | 104,720 | D |
| GUGGENHIME ANDREW PRESIDENT AND CFO | 2024-07-18 | Sale 10b5-1 | −3,095 | $80.12 | $247,956 | 101,625 | D |
| GUGGENHIME ANDREW PRESIDENT AND CFO | 2024-07-18 | Sale 10b5-1 | −2,500 | $81.06 | $202,638 | 99,125 | D |
| GUGGENHIME ANDREW PRESIDENT AND CFO | 2024-07-18 | Sale 10b5-1 | −1,479 | $82.32 | $121,747 | 97,646 | D |
| GUGGENHIME ANDREW PRESIDENT AND CFO | 2024-07-18 | Sale 10b5-1 | −926 | $83.14 | $76,985 | 96,720 | D |
| Derivatives | |||||||
| GUGGENHIME ANDREW PRESIDENT AND CFO | 2024-07-18 | Option exercise · Stock Option (right to buy) 10b5-1 | −8,000 | 336,827 | D | ||
| Open-market sales · 8,000 sh · avg $81.17 · $649,325 | |||||||
Loading xslF345X05/wk-form4_1721678591.xml…